Abbott Laboratories 10-Q Summary: Period Ended June 30, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006, and the six months ended on that date. Abbott Laboratories is a global healthcare company operating in pharmaceuticals, diagnostics, nutritionals, and vascular products. The reporting period is significantly impacted by the acquisition of Guidant's vascular intervention and endovascular solutions businesses on April 21, 2006, for approximately $4.1 billion. Additionally, the company adopted SFAS No. 123(R) regarding share-based payments on January 1, 2006.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Net Sales | $10,684.6 million | $10,906.5 million |
| Net Earnings | $1,477.1 million | $1,714.9 million |
| Diluted EPS | $0.96 | $1.09 |
| Operating Cash Flow | $2,688.7 million | $2,331.9 million |
| Free Cash Flow (Approx.) | $2,017.3 million | $1,698.1 million |
| Long-Term Debt | $8,174.7 million | $4,571.5 million |
| Cash and Equivalents | $790.9 million | $1,447.2 million (End of 2005) |
| Gross Margin | 57.3% | 52.7% |
Note: Free Cash Flow calculated as Operating Cash Flow less Acquisitions of property and equipment ($671.4M).
Material Changes vs. Prior Period
- Revenue Decline: Consolidated net sales decreased 2.0% year-over-year. This decline is primarily due to the cessation of distribution activities for Boehringer Ingelheim (BI) products effective January 1, 2006, and the negative impact of a stronger U.S. dollar. Excluding BI products, sales increased 8.3%.
- Profitability Pressure: Net earnings decreased 13.8% to $1.48 billion. This was driven by a $493 million charge for acquired in-process research and development (IPR&D) related to the Guidant acquisition, increased share-based compensation expense ($211 million vs. $15 million in 2005), and higher interest expense.
- Segment Performance:
- Vascular Products: Sales surged 195.7% to $342 million due to the Guidant acquisition.
- Pharmaceuticals: Sales declined 11.1% to $5.9 billion, largely due to the BI agreement change and generic competition for Biaxin.
- Nutritionals: Sales grew 12.7% to $2.19 billion, driven by international pediatric volume and Synagis revenue.
- Balance Sheet: Long-term debt increased by $3.6 billion, primarily due to the issuance of $4.0 billion in new debt to fund the Guidant acquisition and pay down commercial paper. Cash and equivalents decreased by $2.1 billion due to acquisition outflows.
Guidance, Outlook, and Risks
- Guidance: Management estimates the effective tax rate for the last six months of 2006 will be between 23.5% and 24.0%. The FDA's "approvable letter" for TAP Pharmaceutical's febuxostat is noted to have no impact on previously stated 2006 EPS guidance.
- Investment in Boston Scientific: Abbott holds 64.6 million shares of Boston Scientific common stock (cost basis $1.326 billion; fair value $976 million at June 30). The decline in fair value resulted in a $157 million charge to Accumulated Other Comprehensive Income. Management considers this decline temporary. Abbott is required to dispose of these shares by October 2008, subject to trading restrictions.
- Liquidity: Working capital decreased to $2.2 billion from $4.0 billion at year-end 2005 due to cash used for acquisitions. The company maintains $3.0 billion in unused lines of credit. Credit ratings remain strong (AA by S&P, A1 by Moody's), though Moody's changed its outlook to "negative" following the acquisition announcement.
- Legal and Contingencies:
- Guidant Litigation: Abbott assumed certain litigation reserves from Guidant, increasing the estimated range of possible loss for legal proceedings to $175 million–$370 million (reserve balance: $205 million).
- Pharmaceutical Pricing: The DOJ intervened in a whistle-blower lawsuit alleging inflated prices for Medicaid/Medicare drugs. Abbott cannot estimate the potential loss, but resolution could be material to quarterly cash flows.
- Patent Disputes: Ongoing litigation regarding Depakote, Tricor, Humira, and Biaxin. Settlements in principle were reached with Teva and Ranbaxy regarding Biaxin XL.
Investor Verification Checklist
- Guidant Integration: Verify the timeline for separating accounting processes from Boston Scientific and the realization of synergies from the $4.1 billion acquisition.
- Boston Scientific Exposure: Monitor the fair value of the $1.3 billion Boston Scientific investment and the ability to exit the position by the October 2008 deadline given trading restrictions.
- Pharmaceutical Pipeline: Assess the impact of the Boehringer Ingelheim distribution agreement termination on future revenue and the performance of key drugs like Humira and Tricor.
- Legal Reserves: Track developments in the DOJ price-fixing investigation and the assumed Guidant litigation to determine if the $205 million reserve is sufficient.
- Debt Servicing: Review the impact of the $4 billion new debt issuance on future interest expenses and cash flow coverage.